Fulgent Oncology

What Fulgent Oncology does

Fulgent Oncology is a B2B clinical laboratory diagnostics brand that provides genomic and pathology testing services to oncologists, pathologists, and cancer care teams across the United States. The company operates as a brand under Fulgent Genetics (NASDAQ: FLGT), a publicly traded technology company founded in 2011 with stated expertise in genomics, bioinformatics, and artificial intelligence; Fulgent Oncology's diagnostic services are delivered through the Fulgent Genetics subsidiaries CSI Laboratories and Inform Diagnostics, which together contribute more than 50 years of combined pathology experience. Fulgent Oncology was formed via the rebranding of CSI Laboratories and consolidates the cancer diagnostics business under the parent's brand identity.

The company's core offering is the Lumera product line, which combines next-generation sequencing (NGS) with machine learning capabilities to interpret genomic data and generate clinically actionable cancer profiles. The portfolio is organized by clinical use case: solid tumor profiling (Lumera Xpanded Profile, Lumera NGS Profile, Lumera Liquid Biopsy), hematopathology (Lumera Comprehensive Hematological Evaluation, Lumera Heme NGS Profile), specialized molecular profiling (Lumera HRR-HRD Molecular Profile for PARP-inhibitor guidance), and hereditary cancer testing. The Xpanded and Comprehensive options bundle full clinical case review and reflex testing into a single streamlined report, distinguishing Fulgent Oncology from commodity reference labs. The company is HIPAA-compliant and operates under standard clinical laboratory regulatory frameworks.

Fulgent Oncology's revenue model is professional-services-based clinical laboratory testing, with quote-based or contract pricing to healthcare providers and payers (pricing is not publicly disclosed). Go-to-market is enterprise field sales: dedicated account managers manage relationships with healthcare-provider clients, a client portal supports ordering and results access, and the marketing mix relies on the company website plus professional resources (requisitions, billing, accreditation, portals) rather than broad consumer advertising. Customers are primarily practicing oncologists, pathologists, and cancer care teams; patients are an indirect downstream segment reached via their providers. Distribution is domestic U.S. only, with no disclosed international footprint.

Name

Fulgent Oncology

Legal name

Fulgent Oncology

Website

https://fulgentoncology.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

101–250 employees

Short description

Fulgent Oncology is a U.S. specialty clinical laboratory brand under Fulgent Genetics that delivers NGS-based genomic and pathology cancer diagnostics — the Lumera product line — to oncologists, pathologists, and cancer care teams via account-manager-based B2B sales.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Reference & Esoteric Testing Laboratories (HLAFAMAJ), Oncology Pathways & Precision Medicine Decision Support (HLACAGAH), Clinical Decision Support & Workflow Integration (EHR/oncology systems) (HLAAANAE)

Keywords

• Cancer diagnostics
• Genomic profiling
• Next-generation sequencing
• Liquid biopsy testing
• Hereditary cancer testing

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Laboratory Diagnostic Testing Services: Clinical laboratory testing services for cancer diagnostics including genomic profiling, liquid biopsy, and hereditary cancer testing. Services are provided to healthcare providers and cancer care teams with results delivered through clinical reports.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Fulgent Oncology operates a clinical laboratory that delivers precision cancer diagnostics through its Lumera® product line, combining next-generation sequencing with machine learning to produce genomic profiling for solid tumors, hematological malignancies, liquid biopsy, and hereditary cancer testing. Services are ordered by healthcare providers and cancer care teams, with results delivered through streamlined consolidated clinical reports that include full case review and reflex testing.

Product overview

Fulgent Oncology provides a unified diagnostic platform offering the Lumera product line, which combines next-generation sequencing with machine learning capabilities for precision cancer medicine. The portfolio includes multiple testing options organized by cancer type: solid tumor testing (Lumera Xpanded Profile, Lumera NGS Profile, Lumera Liquid Biopsy), hematopathology testing (Lumera Comprehensive Hematological Evaluation, Lumera Heme NGS Profile), and specialized molecular profiling (Lumera HRR-HRD Molecular Profile). Additional offerings include hereditary cancer testing. The Lumera Xpanded and Comprehensive options include full clinical case review and additional reflex testing as needed, all delivered in streamlined reports. The company also offers single gene testing with the ability to reflex to comprehensive profiles.

Differentiator

Problem solved

Functional benefit

Brands

• Lumera: A product line combining next-generation sequencing with machine learning capabilities to deliver highly personalized results. Includes Lumera Xpanded Profile, Lumera NGS Profile, Lumera Liquid Biopsy, Lumera Comprehensive Hematological Evaluation, Lumera Heme NGS Profile, and Lumera HRR-HRD Molecular Profile.

Products and services

• Lumera Xpanded Solid Tumor Profile Comprehensive solid tumor testing profile offering full clinical case review and additional reflex testing as needed, with results summarized in a streamlined report for oncologists and cancer care teams.
• Lumera NGS Profile for Solid Tumors Next-generation sequencing profile for solid tumor analysis using advanced genomic sequencing technology to identify cancer-related biomarkers for oncology professionals.
• Lumera Liquid Biopsy Non-invasive liquid biopsy testing that analyzes blood samples to detect and characterize tumors through circulating tumor DNA analysis for cancer care teams.
• Lumera Comprehensive Hematological Evaluation Comprehensive hematopathology evaluation including full clinical case review and additional reflex testing as needed for blood and lymphoid cancers, serving oncologists and pathologists.
• Lumera Heme NGS Profile Next-generation sequencing profile specifically designed for hematological malignancies, providing detailed genomic analysis of blood cancers for hematologists and oncologists.
• Lumera HRR-HRD Molecular Profile Molecular profile focusing on homologous recombination repair (HRR) and homologous recombination deficiency (HRD) to guide targeted therapy selection in cancer treatment.
• Hereditary Cancer Testing Genetic testing service to identify inherited cancer risk mutations and inform preventive care and treatment decisions for patients and their providers.

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Emerging players

• Personalis: NGS-based cancer genomics provider with NeXT Personal and ImmunoID offerings, including liquid biopsy. Comparable in tumor profiling, MRD, and pharma/biopharma CDx partnerships, though smaller and more focused.
• Natera: Molecular diagnostics company expanding into oncology with Signatera MRD and tumor profiling assays. Comparable as a competing NGS-based oncology diagnostics provider with proprietary technology and overlapping hospital channel.

Direct peers

• Guardant Health: Specializes in liquid biopsy and ctDNA-based oncology testing, including the Guardant360 CDx. Directly comparable to Fulgent Oncology's Lumera Liquid Biopsy in technology and target use cases for therapy selection and MRD monitoring.
• Caris Life Sciences: Provides molecular profiling (MI Profile), liquid biopsy, and AI-driven oncology analytics across solid tumors. Directly comparable in comprehensive NGS-based profiling and precision oncology workflows for oncologists.
• NeoGenomics: Specialized oncology reference laboratory offering NGS, liquid biopsy, hematopathology, and hereditary cancer testing. Closely comparable to Fulgent Oncology's full Lumera portfolio and B2B laboratory services model.
• Tempus Labs: AI-enabled precision medicine company offering NGS tumor profiling, liquid biopsy, and molecular testing with proprietary data analytics. Directly comparable in NGS+ML oncology diagnostics and target customer segment (oncologists, hospitals).
• Foundation Medicine: A Roche subsidiary offering comprehensive NGS-based genomic profiling of solid tumors and hematologic malignancies. Directly comparable to Fulgent Oncology's Lumera NGS and Xpanded solid tumor profiles across the same oncologist customer base.

Broad incumbents

• Quest Diagnostics: Large national clinical laboratory offering oncology NGS, hematopathology, and hereditary cancer testing. Comparable as an enterprise-scale B2B lab diagnostics provider, though operating across a much broader non-oncology portfolio.
• Exact Sciences: Larger molecular diagnostics company with the Oncotype DX franchise and growing oncology portfolio. Comparable as a broad-based oncology molecular testing player, though with much larger scale and broader product reach.
• Labcorp: Major clinical laboratory network with oncology molecular diagnostics, liquid biopsy, and pathology services through its diagnostics business. Comparable as a large-scale reference laboratory competitor in oncology testing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/fulgent-oncology

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fulgent Oncology